Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 3—March 2004
Research

Neutralizing Antibodies and Sin Nombre Virus RNA after Recovery from Hantavirus Cardiopulmonary Syndrome

Chunyan Ye*, Joseph B. Prescott*, Robert A. Nofchissey*, Diane Goade*, and Brian Hjelle*Comments to Author 
Author affiliations: *University of New Mexico School of Medicine, Albuquerque, New Mexico, USA

Main Article

Table

Demographic and clinical characteristics of 21 patients with history of Sin Nombre virus infectiona

Patient Age at time of illness Sex Date admitted Day serum collected Location Severityb
1
 10
 M
 30 Mar 1999
 589
 NM
 I
2
 44
 F
 4 Dec 1995
 1789
 NM
 IIE
3
 28
 F
 5 Apr 1999
 592
 NM
 0
4
 28
 F
 3 Apr 1999
 566
 WA
 II
5
 42
 M
 15 Jun 1999
 94
 NM
 I
6
 29
 F
 1 May 1998
 1063
 NM
 I
7
 18
 F
 11 Aug 1998
 512
 CO
 IIE
8
 44
 F
 29 Mar 1994
 1627
 NM
 II
9
 43
 M
 1 Sep 2000
 231
 AZ
 IIE
10
 41
 M
 20 Mar 1997
 1436
 KS
 II
11
 39
 F
 6 Mar 2001
 85
 NM
 II
12
 50
 M
 20 Aug 1998
 334
 NM
 IIE
13
 34
 F
 15 Jul 1999
 92
 CO
 I
14
 44
 F
 3 Nov 1997
 1281
 KS
 II
15
 19
 F
 18 Oct 2000
 132
 MT
 II
16
 27
 M
 23 Jul 1997
 1356
 NM
 I
17
 27
 F
 27 Jan 1998
 1196
 KS
 I
18
 23
 F
 30 Oct 1999
 161
 NM
 IIE
19
 16
 M
 19 Sep 1997
 1419
 TX
 II NO (15)
20
 21
 F
 27 May 1994
 2268
 NM
 II
21 44 M 20 Dec 1997 1056 WI II

aF, female; M, male; NM, New Mexico, WA, Washington, CO, Colorado; AZ, Arizona; KS, Kansas; MT, Montana; TX, Texas; WI, Wisconsin.
bSeverity scale: Class 0, prodromal symptoms with seroconversion but with no cardiopulmonary manifestations; Class I, prodrome symptoms with hypoxia but not requiring endotracheal intubation; Class II, survived but required endotracheal intubation; Class IIE, required extracorporeal membrane oxygenation; II NO, treated with inhalational nitric oxide. Because they required endotracheal intubation, patients in Class II are regarded as having been more severely ill than those in Classes 0 and I.

Main Article

References
  1. Schmaljohn  C, Hjelle  B. Hantaviruses: a global disease problem. Emerg Infect Dis. 1997;3:95–104. DOIPubMedGoogle Scholar
  2. Childs  JE, Ksiazek  TG, Spiropoulou  CF, Krebs  JW, Morzunov  S, Maupin  GO, Serologic and genetic identification of Peromyscus maniculatus as the primary rodent reservoir for a new hantavirus in the southwestern United States. J Infect Dis. 1994;169:1271–80.PubMedGoogle Scholar
  3. Young  JC, Hansen  GR, Graves  TK, Deasy  MP, Humphreys  JG, Fritz  CL, The incubation period of hantavirus pulmonary syndrome. Am J Trop Med Hyg. 2000;62:714–7.PubMedGoogle Scholar
  4. Mertz  GJ, Hjelle  BL, Bryan  RT. Hantavirus infection. Adv Intern Med. 1997;42:369–421.PubMedGoogle Scholar
  5. Jenison  S, Yamada  T, Morris  C, Anderson  B, Torrez-Martinez  N, Keller  N, Characterization of human antibody responses to four corners hantavirus infections among patients with hantavirus pulmonary syndrome. J Virol. 1994;68:3000–6.PubMedGoogle Scholar
  6. Bharadwaj  M, Nofchissey  R, Goade  D, Koster  F, Hjelle  B. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis. 2000;182:43–8. DOIPubMedGoogle Scholar
  7. Hjelle  B, Jenison  S, Torrez-Martinez  N, Herring  B, Quan  S, Polito  A, Rapid and specific detection of Sin Nombre virus antibodies in patients with hantavirus pulmonary syndrome by a strip immunoblot assay suitable for field diagnosis. J Clin Microbiol. 1997;35:600–8.PubMedGoogle Scholar
  8. Botten  J, Mirowsky  K, Kusewitt  D, Bharadwaj  M, Yee  J, Ricci  R, Experimental infection model for Sin Nombre hantavirus in the deer mouse (Peromyscus maniculatus). Proc Natl Acad Sci U S A. 2000;97:10578–83. DOIPubMedGoogle Scholar
  9. Crowley  MR, Katz  RW, Kessler  R, Simpson  SQ, Levy  H, Hallin  GW, Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation [see comments] [published erratum appears in Crit Care Med 1998 Apr;26:806]. Crit Care Med. 1998;26:409–14. DOIPubMedGoogle Scholar
  10. Kenyon  RH, Condie  RM, Jahrling  PB, Peters  CJ. Protection of guinea pigs against experimental Argentine hemorrhagic fever by purified human IgG: importance of elimination of infected cells. Microb Pathog. 1990;9:219–26. DOIPubMedGoogle Scholar
  11. Enria  DA, Briggiler  AM, Fernandez  NJ, Levis  SC, Maiztegui  JI. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet. 1984;2:255–6. DOIPubMedGoogle Scholar
  12. Maiztegui  JI, Fernandez  NJ, de Damilano  AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 1979;2:1216–7. DOIPubMedGoogle Scholar
  13. Jahrling  PB, Peters  CJ. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun. 1984;44:528–33.PubMedGoogle Scholar
  14. Terajima  M, Hendershot  JD III, Kariwa  H, Koster  FT, Hjelle  B, Goade  D, High levels of viremia in patients with the Hantavirus pulmonary syndrome. J Infect Dis. 1999;180:2030–4. DOIPubMedGoogle Scholar
  15. Rosenberg  RB, Waagner  DC, Romano  MJ, Kanase  HN, Young  RB. Hantavirus pulmonary syndrome treated with inhaled nitric oxide. Pediatr Infect Dis J. 1998;17:749–52. DOIPubMedGoogle Scholar

Main Article

Page created: February 08, 2011
Page updated: February 08, 2011
Page reviewed: February 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external